As drug product pipelines grow more complex — across both injectable biologics and small molecule therapies — development and manufacturing are increasingly defined by the ability to balance speed, scalability, and precision. From formulation through fill-finish, these critical stages demand specialized expertise, robust quality systems, and reliable capacity to ensure timelines, compliance, and product integrity stay on track.
That’s why the Outsourced Pharma Capabilities Update (OPCU) is designed to go beyond a simple view of capacity and instead highlight what truly differentiates today’s CDMOs: their technologies, experience, facility footprints, and real-time readiness to support a range of programs, from oral solid doses to sterile and advanced modalities.
Through short, focused digital sessions, CDMOs present a practical look at their capabilities across key development and manufacturing stages. These briefings give biopharma teams, consultants, and investors clear, actionable insight into available options — making it easier to assess fit, reduce risk, and accelerate decision-making.
Recent Sessions Available On-Demand
Small Molecule Drug Substance/Small Molecule Drug Product – 3/11/2026
Cell & Gene Therapy/Analytical Service – 3/12/2026
Large Molecule Manufacturing/Fill-Finish – 3/10/2026
Upcoming OPCU Topics & Times
Mammalian Cell Culture | 5/19/2026, AM Session
Highly Potent Drug Development & Manufacturing | 5/19/2026, PM Session
Combination Products & Drug Delivery | 5/20/2026, AM Session
Large Molecule | 5/20/2026, PM Session
Access more on-demand OPCU recordings and upcoming sessions here.
